A5018739853- CAR-T cell therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Virus-based gene therapy research
- Acute Myeloid Leukemia Research
- Nanoparticle-Based Drug Delivery
- COVID-19 and Mental Health
- Molecular Biology Techniques and Applications
- Cancer-related Molecular Pathways
- Hippo pathway signaling and YAP/TAZ
- Biosensors and Analytical Detection
- interferon and immune responses
- Immune cells in cancer
- Chronic Lymphocytic Leukemia Research
- MicroRNA in disease regulation
- Silicon Carbide Semiconductor Technologies
- Wnt/β-catenin signaling in development and cancer
- COVID-19 Clinical Research Studies
Case Comprehensive Cancer Center
2025
Case Western Reserve University
2019-2024
Chimeric antigen receptor T cells (CAR-T cell) targeting CD19 are effective against several subtypes of CD19-expressing hematologic malignancies. Centralized manufacturing has allowed rapid expansion this cellular therapy, but it may be associated with treatment delays due to the required logistics. We hypothesized that point care CAR-T on automated CliniMACS Prodigy® device allows reproducible and fast delivery for patients non-Hodgkin’s lymphoma. Here we describe cell results characterize...
Abstract Chimeric antigen receptor T-cell (CAR-T cell) therapy directed at CD19 produces durable remissions in the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL). Nonetheless, many patients receiving CAR-T cells fail to respond for unknown reasons. To reveal changes 4-1BB–based and identify biomarkers response, we used single-cell RNA sequencing protein surface marker profiling patient pre- postinfusion into with NHL. At transcriptional levels, note evolution toward a...
This review focuses on the use of chimeric antigen receptor (CAR)-T cell therapy to treat non-Hodgkin’s lymphoma (NHL), a classification heterogeneous malignant neoplasms lymphoid tissue. Despite various conventional and multidrug chemotherapies, poor prognosis for NHL patients remains has prompted utilization groundbreaking personalized therapies such as CAR-T cells. cells are T engineered express CAR that enables specifically lyse tumor with extracellular expression choice. A is composed...
Point-of-care manufacture of chimeric antigen receptor (CAR)-T cells can significantly reduce the time from apheresis to infusion. We conducted a dual-institution phase I trial aimed evaluating safety and feasibility this manufacturing model. CASE 2417 was clinical trial. Adults with relapsed or refractory CD19 positive non-Hodgkin lymphoma (R/R NHL) treated ≥2 prior systemic therapies were eligible. MB-CART-19 is an anti-CD19 CAR T-cell product manufactured using CliniMACS Prodigy device...
SARS CoV-2 has caused a global pandemic leading to significant morbidity and mortality. There is need elucidate further understand the implications of COVID-19 disease on immune system develop improved therapeutic strategies. In particular, Natural Killer (NK) cells play an essential role in mediating innate response against viral infections. To better immunity COVID-19, we characterized phenotype circulating NK from 74 patients 25 controls. Through evaluating protein expression activating...
<div>Abstract<p>Chimeric antigen receptor T-cell (CAR-T cell) therapy directed at CD19 produces durable remissions in the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL). Nonetheless, many patients receiving CAR-T cells fail to respond for unknown reasons. To reveal changes 4-1BB–based and identify biomarkers response, we used single-cell RNA sequencing protein surface marker profiling patient pre- postinfusion into with NHL. At transcriptional levels, note evolution...
<div>Abstract<p>Chimeric antigen receptor T-cell (CAR-T cell) therapy directed at CD19 produces durable remissions in the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL). Nonetheless, many patients receiving CAR-T cells fail to respond for unknown reasons. To reveal changes 4-1BB–based and identify biomarkers response, we used single-cell RNA sequencing protein surface marker profiling patient pre- postinfusion into with NHL. At transcriptional levels, note evolution...
Supplementary Figure from Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma
Supplementary Data from Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma
Supplementary Figure from Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma
Supplementary Data from Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma
Abstract Pediatric Acute Myeloid Leukemia (AML) with a FLT3 internal tandem duplication (FLT3-ITD) is challenging disease due to poor outcomes in many patients. The 4-year progression-free survival still only 31%. Current biomarkers are insufficient predict why certain patients FLT3-ITD AML relapse and others do not. development of prognostic pediatric may help improve the management these We acquired panel 37 diagnostic samples 18 from (relapse within 3 years) 19 favorable outcome that did...
Abstract Chimeric antigen receptor T cell (CAR-T cell) therapy is known to produce durable remissions in the treatment of CD19 + relapsed/refractory B malignancies. Nonetheless, a significant portion patients receiving experience poor outcomes acute response for unknown reasons. Given decreased expansion and persistence CD8 CAR-T cells outcome groups, this failure may be attributed dysfunction. However, comparison post-infusion transcriptional profiles phenotypes between favorable groups has...